Related Experiment Video

Updated: Apr 6, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

1.9K

Role of anticoagulant therapy in liver disease

Elisabeth P C Plompen1, Jeoffrey N L Schouten1, Harry L A Janssen2

  • 1Department of Gastroenterology and Hepatology, Erasmus Medical Center, 's Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.

Hepatology International
|July 24, 2015
PubMed

Insights

Anticoagulant therapy is crucial for liver diseases like Budd-Chiari syndrome and portal vein thrombosis. It improves survival and shows promise in preventing liver fibrosis and disease progression in cirrhosis.

Area of Science:

  • Hepatology
  • Hematology
  • Thrombosis Research

Background:

  • Anticoagulant therapy is a key treatment for various liver diseases.
  • Survival rates in Budd-Chiari syndrome (BCS) have improved with anticoagulation as a primary strategy.
  • Anticoagulation is indicated for acute portal vein thrombosis (PVT) and considered for chronic PVT with risk factors.

Purpose of the Study:

  • To review the role of anticoagulation in managing liver diseases, particularly BCS and PVT.
  • To explore the impact of anticoagulation on liver fibrosis and disease progression in cirrhosis.
  • To highlight anticoagulation as a potential antifibrotic treatment.

Main Methods:

  • Literature review of studies on anticoagulation in liver diseases.
  • Analysis of evidence regarding anticoagulation in Budd-Chiari syndrome and portal vein thrombosis.
  • Examination of research on anticoagulation's effects on fibrogenesis and cirrhosis.

Main Results:

  • Anticoagulation significantly improves survival in Budd-Chiari syndrome.
  • It is a standard treatment for acute portal vein thrombosis and beneficial for PVT in cirrhosis.
  • Evidence suggests anticoagulation can prevent or improve liver fibrosis and disease progression.

Conclusions:

  • Anticoagulant therapy is essential for managing BCS and PVT, improving patient outcomes.
  • The coagulant balance in chronic liver disease is altered, making anticoagulation a complex but potentially beneficial intervention.
  • Anticoagulation emerges as a promising therapeutic strategy for antifibrotic effects in liver disease.

Keywords:
Anticoagulant therapyCoagulopathyHepatic fibrosisHepatic venous outflowPortal vein thrombosis

More Related Videos

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection06:00

Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection

Published on: December 30, 2025

550

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
337
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
786